Ken Griffin Lantern Pharma Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.42 - $4.83 $1,710 - $2,415	500 Added 8.93%	6,100 $22,000
Q2 2024 Aug 14, 2024	SELL	$3.91 - $9.51 $10,948 - $26,628	-2,800 Reduced 33.33%	5,600 $26,000
Q1 2024 May 15, 2024	BUY	$3.73 - $10.65 $29,840 - $85,200	8,000 Added 2000.0%	8,400 $73,000
Q4 2023 Feb 14, 2024	SELL	$2.48 - $4.39 $15,872 - $28,095	-6,400 Reduced 94.12%	400 $1,000
Q3 2023 Nov 14, 2023	BUY	$3.41 - $5.51 $22,506 - $36,366	6,600 Added 3300.0%	6,800 $23,000
Q2 2023 Aug 14, 2023	SELL	$4.56 - $6.02 $911 - $1,204	-200 Reduced 50.0%	200 $1,000
Q4 2022 Feb 14, 2023	SELL	$4.19 - $6.04 $59,079 - $85,164	-14,100 Reduced 97.24%	400 $2,000
Q3 2022 Nov 14, 2022	BUY	$4.59 - $6.5 $66,555 - $94,250	14,500 New	14,500 $69,000

1.31M

39.8K

6.1K

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $37M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.